Clinical Trial Update: Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating erlotinib in patients with advanced non-small cell lung cancer has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib) (erlotinib)

Snippet

Sponsor: National Guard Health Affairs | Conditions: Non-small Cell Lung Cancer Metastatic | Phase 4 | Status: SUSPENDED